J Korean Cancer Assoc.
2000 Aug;32(4):682-689.
Concurrent Chemoradiation Therapy with Cisplatin and Oral Etoposide for Locally Advanced Non-small Cell Lung Cancer
- Affiliations
-
- 1Departments of Internal Medicine, College of Medicine, Korea University, Seoul, Korea.
- 2Departments of Radiation-Oncology, College of Medicine, Korea University, Seoul, Korea.
- 3Departments of Chest Surgery College of Medicine, Korea University, Seoul, Korea.
Abstract
-
PURPOSE: Prognosis of locally advanced inoperable non-small cell lung cancer (NSCLC) treated
with radiation therapy alone has been disappointing. In recent years, concurrent chemoradiation
therapy has potential of improving both local and metastatic disease-free survival. This phase
II study was undertaken to determine the feasibility, toxicity, response rate, local control rate,
and survival duration of locally advanced NSCL patients treated with concurrent chemoradiation
using cisplatin and oral etoposide.
MATERIAL AND METHODS: Forty-seven patients were enrolled and forty-one patients were evaluable.
Chemotheray consisted of cisplatin 50 mg/m2/IV on days 1 and 8 and oral etoposide 100 mg/day
on days 1 to 5 and 8 to 12 which was repeated, every 4 weeks for two cycles during radiation
therapy. Radiation therapy was administered to a total dose of 6300 cGY.
RESULTS
Among 41 evaluable patients, six patients achieved complete response, and twenty had partial response, for an overall response rate of 63.4% (95% confidence interval; 48.4% to 75.4%). Stable disease was reported in 10 patients (24.4%) and another 5 (12.2%) showed disease pro gression. Overall survival rate was 76% at 1 year, 34% at 2 years. Median survival duration was 17 months (range; 3 to 41 ). Eighty-three percents of patients had radiation pneumonitis but only one patients needed medical treatment.
CONCLUSION
Concurrent chemoradiation therapy with cisplatin and oral etoposide at this level is a well tolerated and feasible.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Treatment of Small Cell Lung Cancer
- Chemotherapy for Small Cell Lung Cancer
- A prospective randomized study of cisplatin versus PEV(cisplatin, etoposide, vinblastine) chemotherapy in advanced non-small cell lung cancer
- Phase II trial of sequential VP-16, cisplatin combination chemotherapy and radiotherapy for locally advanced (stage III) non-small cell lung cancer
- Phase II Study of Ifosfamide, Etoposide and Cisplatin(IEP) Chemotherapy for Advanced Non-Small Cell Lung Cancer
